2 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Castration-resistant Prostate Cancer: new trials by email Literature Review of Castration-resistant Prostate Cancer trials Research Report on Castration-resistant Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) HC-1119, Enzalutamide - Prostate Cancer Metastatic, Castration-resistant Prostate Cancer | Phase 3 | Terminated | Hinova Pharmaceuticals USA, Inc. | 104 | 2021-03-15 | 2024-08-19 |
| F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer F-Choline-PET - Castration-resistant Prostate Cancer | Phase 2 / Phase 3 | Terminated | University Hospital, Grenoble | 12 | 2013-12-01 | 2016-04-28 |
enzalutamide (1)
Hinova Pharmaceuticals USA, Inc. (1) · University Hospital, Grenoble (1)
France (2) · Australia (1) · Austria (1) · Canada (1) · Denmark (1) · Finland (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Russia (1) · Spain (1) · United Kingdom (1) · United States (1)